$SNWV

SANUWAVE Health, Inc.

SANUWAVE is a medical device company that develops and markets directed-energy products for wound care. Its focus is regenerative medicine using noninvasive ultrasound to promote tissue repair and regeneration. UltraMIST is its only commercial product: a system that delivers low-frequency, non-thermal ultrasound through a fluid mist to treat a variety of acute and chronic wounds. The system is used in hospitals, clinics, wound centers, nursing homes, skilled nursing facilities and patient homes, with treatment administered by a healthcare professional. SANUWAVE sells systems through direct sales representatives, independent distributors and resellers, primarily in the United States. Customers purchase an UltraMIST system and sterile, single-use applicators for treatments; applicators are sold in cases of 12. The company is headquartered in Eden Prairie, Minnesota, where it has office, product development, quality control and warehouse space.

No enriched coverage for $SNWV in the last 7 days.

No SEC Form 4 filings for $SNWV in the last 30 days.

See all $SNWV insider activity →
Med

Sanuwave Q3 2026 slides show 24% revenue drop, system sales plunge

Sanuwave Health (SNWV) reported a 24% revenue decline to $8.6M in Q3 2026, missing expectations. Operating loss of $1.1M compared to prior-year income. System sales dropped 74% YoY, while consumables grew 2%. CMS rule changes disrupted the wound care market. Shares rose 8.51% premarket despite challenges, reflecting long-term hospital strategy focus.

Sanuwave Announces Q3 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q3 FY2026 Financial Results Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. Q3 2026 gross margin was 77.3%, versus 77.6% in Q3 2025. GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 millio

SNWV sentiment & insider activity

Recent SNWV coverage spans earnings, corporate actions and regulation.

What's driving SNWV

AlphAI scores every news story that mentions SNWV with an AI model for sentiment and relevance, and aggregates insider trades from SANUWAVE Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SNWV

Score
$SNWVMedEarnings

Sanuwave Announces Q3 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q3 FY2026 Financial Results Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. Q3 2026 gross margin was 77.3%, versus 77.6% in Q3 2025. GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 millio

$SNWVLowDebt financing· $5K

SANUWAVE Health, Inc. (SNWV): Entry into a Material Definitive Agreement

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 28, 202 6, Sanuwave Health, Inc., a Nevada corporation (the “Company”), entered into Amendment No. 1 to Credit Agreement and Waiver (the “Amendment”) to the credit agreement (the “Credit Agreement”), dated as of Sep

$SNWVMedAI 8/10

SANUWAVE (SNWV) Q2 2026 Earnings Call Transcript

SANUWAVE (SNWV) reported Q2 2026 revenue of $9.7M, down 3% from $10.1M, driven by lower capital equipment sales. UltraMIST applicator revenue rose 13% to $7.3M, while UltraMIST system revenue fell 34% to $2.3M. The company posted a $0.7M net loss and withdrew FY2026 guidance amid proposed 2027 Medicare reimbursement cuts.

$SNWVMedEarnings

Sanuwave Announces Q2 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q2 FY2026 Financial Results Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 20

$SNWVMedAI 8/10

What's Going On With SANUWAVE Health Stock On Friday? - SANUWAVE Health (NASDAQ:SNWV)

Sanuwave Health (NASDAQ:SNWV) said it expects Q2 2026 revenue of $9.6 million to $9.8 million, above prior guidance of $8.5 million to $9.5 million. The company noted Q2 revenue is about 3% to 5% lower year over year from $10.1 million. It cited pressured capital sales but record consumable applicator momentum and offered trade-in and support programs. Shares were down 4.44% to $6.36.

Related tickers